| Literature DB >> 1720991 |
B W Kirkham1, C Pitzalis, G H Kingsley, I C Chikanza, S Sabharwal, C Barbatis, R Grahame, T Gibson, P L Amlot, G S Panayi.
Abstract
Six patients with rheumatoid arthritis were treated with a CD7 mouse monoclonal antibody, RFT2, daily for 15 days. Only two patients had a significant improvement in clinical disease activity which lasted 7-14 days. No serious adverse effects occurred although all patients developed antibodies against mouse immunoglobulin. During treatment T-lymphocyte numbers decreased and T-lymphocyte CD7 expression was absent in all but one patient.Entities:
Mesh：
Substances：
Year: 1991 PMID： 1720991 DOI： 10.1093/rheumatology/30.6.459
Source DB: PubMed Journal: Br J Rheumatol ISSN： 0263-7103